Guggenheim Starts Corbus Pharmaceuticals (CRBP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts CRBP Hot Sheet
Price: $5.38 +2.09%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ: CRBP) with a Buy rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.
Shares of Corbus Pharmaceuticals closed at $10.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: just concluded a highly successful discussion with president Vladimir Putin
- RBC on Semiconductor short interest as of September 30th
- GTCR and Elliott nearing deal for CCC Intelligent Solutions - Bloomberg
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
